1GALD Stock Overview

Operates as a dermatology company worldwide. More details

1GALD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 36.2% below our estimate of its fair value

Earnings are forecast to grow 31.05% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Galderma Group AG Competitors

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.9b

Otsuka Holdings

TSE:4578

JP¥3.9t

Hansoh Pharmaceutical Group

SEHK:3692

HK$141.5b

UCB

ENXTBR:UCB

€29.7b

Price History & Performance

Summary of share price highs, lows and changes for Galderma Group
Historical stock prices
Current Share Price	CHF 102.00
52 Week High	CHF 0
52 Week Low	CHF 0
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1GALD	IT Pharmaceuticals	IT Market
7D	n/a	1.8%	2.1%
1Y	n/a	-14.9%	12.2%

Return vs Industry: Insufficient data to determine how 1GALD performed against the Italian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1GALD performed against the Italian Market.

Price Volatility

Is 1GALD's price volatile compared to industry and market?
1GALD volatility
1GALD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	5.3%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1GALD's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1GALD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	6,545	Flemming Ornskov	www.galderma.com

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.

Galderma Group AG Fundamentals Summary

How do Galderma Group's earnings and revenue compare to its market cap?
1GALD fundamental statistics
Market cap	€24.75b
Earnings (TTM)	€204.20m
Revenue (TTM)	€3.92b

121.2x

P/E Ratio

6.3x

P/S Ratio

Is 1GALD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GALD income statement (TTM)
Revenue	US$4.44b
Cost of Revenue	US$1.36b
Gross Profit	US$3.09b
Other Expenses	US$2.85b
Earnings	US$231.00m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Jul 24, 2025

Earnings per share (EPS)	0.97
Gross Margin	69.48%
Net Profit Margin	5.20%
Debt/Equity Ratio	33.9%

How did 1GALD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 00:59
End of Day Share Price	2025/05/07 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galderma Group AG is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Fulvio Cazzol	Berenberg
Bethan Davies	Berenberg
Victor Floch	BNP Paribas Exane